Literature DB >> 22381899

Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer.

Anand Shah1, Jason A Efstathiou, Jonathan J Paly, Scott D Halpern, Deborah W Bruner, John P Christodouleas, John J Coen, Curtiland Deville, Neha Vapiwala, William U Shipley, Anthony L Zietman, Stephen M Hahn, Justin E Bekelman.   

Abstract

PURPOSE: To investigate patients' willingness to participate (WTP) in a randomized controlled trial (RCT) comparing intensity-modulated radiotherapy (IMRT) with proton beam therapy (PBT) for prostate cancer (PCa). METHODS AND MATERIALS: We undertook a qualitative research study in which we prospectively enrolled patients with clinically localized PCa. We used purposive sampling to ensure a diverse sample based on age, race, travel distance, and physician. Patients participated in a semi-structured interview in which they reviewed a description of a hypothetical RCT, were asked open-ended and focused follow-up questions regarding their motivations for and concerns about enrollment, and completed a questionnaire assessing characteristics such as demographics and prior knowledge of IMRT or PBT. Patients' stated WTP was assessed using a 6-point Likert scale.
RESULTS: Forty-six eligible patients (33 white, 13 black) were enrolled from the practices of eight physicians. We identified 21 factors that impacted patients' WTP, which largely centered on five major themes: altruism/desire to compare treatments, randomization, deference to physician opinion, financial incentives, and time demands/scheduling. Most patients (27 of 46, 59%) stated they would either "definitely" or "probably" participate. Seventeen percent (8 of 46) stated they would "definitely not" or "probably not" enroll, most of whom (6 of 8) preferred PBT before their physician visit.
CONCLUSIONS: A substantial proportion of patients indicated high WTP in a RCT comparing IMRT and PBT for PCa.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22381899     DOI: 10.1016/j.ijrobp.2011.11.072

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  12 in total

1.  Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer.

Authors:  Phillip J Gray; Jonathan J Paly; Beow Y Yeap; Martin G Sanda; Howard M Sandler; Jeff M Michalski; James A Talcott; John J Coen; Daniel A Hamstra; William U Shipley; Stephen M Hahn; Anthony L Zietman; Justin E Bekelman; Jason A Efstathiou
Journal:  Cancer       Date:  2013-02-22       Impact factor: 6.860

Review 2.  Proton beam radiation therapy for prostate cancer-is the hype (and the cost) justified?

Authors:  Phillip J Gray; Jason A Efstathiou
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

3.  Randomized evaluation of trial acceptability by INcentive (RETAIN): Study protocol for two embedded randomized controlled trials.

Authors:  Dustin C Krutsinger; Jacqueline McMahon; Alisa J Stephens-Shields; Brian Bayes; Steven Brooks; Brian L Hitsman; Su Fen Lubitz; Celine Reyes; Robert A Schnoll; S Ryan Greysen; Ashley Mercede; Mitesh S Patel; Catherine Reale; Fran Barg; Jason Karlawish; Daniel Polsky; Kevin G Volpp; Scott D Halpern
Journal:  Contemp Clin Trials       Date:  2018-11-08       Impact factor: 2.226

Review 4.  Cancer patient decision making related to clinical trial participation: an integrative review with implications for patients' relational autonomy.

Authors:  Jennifer A H Bell; Lynda G Balneaves
Journal:  Support Care Cancer       Date:  2015-01-17       Impact factor: 3.603

Review 5.  Clinical controversies: proton therapy for prostate cancer.

Authors:  Kent W Mouw; Alexei Trofimov; Anthony L Zietman; Jason A Efstathiou
Journal:  Semin Radiat Oncol       Date:  2013-04       Impact factor: 5.934

6.  A pilot randomized trial of five financial incentive strategies to increase study enrollment and retention rates.

Authors:  Dustin C Krutsinger; Kuldeep N Yadav; Elizabeth Cooney; Steven Brooks; Scott D Halpern; Katherine R Courtright
Journal:  Contemp Clin Trials Commun       Date:  2019-06-04

Review 7.  Proton beam therapy and localised prostate cancer: current status and controversies.

Authors:  J A Efstathiou; P J Gray; A L Zietman
Journal:  Br J Cancer       Date:  2013-03-12       Impact factor: 7.640

8.  Willingness to participate in clinical trials among patients of Chinese heritage: a meta-synthesis.

Authors:  Alexander Limkakeng; Amruta Phadtare; Jatin Shah; Meenakshi Vaghasia; Ding Ying Wei; Anand Shah; Ricardo Pietrobon
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

9.  Will they participate? Predicting patients' response to clinical trial invitations in a pediatric emergency department.

Authors:  Yizhao Ni; Andrew F Beck; Regina Taylor; Jenna Dyas; Imre Solti; Jacqueline Grupp-Phelan; Judith W Dexheimer
Journal:  J Am Med Inform Assoc       Date:  2016-04-27       Impact factor: 4.497

10.  Systematic review of methodology used in clinical studies evaluating the benefits of proton beam therapy.

Authors:  Mercy Ofuya; Lucy McParland; Louise Murray; Sarah Brown; David Sebag-Montefiore; Emma Hall
Journal:  Clin Transl Radiat Oncol       Date:  2019-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.